Posted by Michael Wonder on 24 May 2021
Boehringer Ingelheim's investigational treatment for cognitive impairment associated with schizophrenia receives FDA breakthrough therapy designation
24 May 2021 - BI 425809, a novel glycine transporter-1 (GlyT1) inhibitor to be studied in first of its kind Phase 3 trials, incorporating speech analytics and virtual reality functional capacity assessments.
Boehringer Ingelheim today announced that the US FDA has granted breakthrough therapy designation for BI 425809 for the treatment of cognitive impairment associated with schizophrenia.
